Feverfew Benefits

Feverfew (Tanacetum parthenium, family Asteraceae) has one serious modern use and a reputation that runs well ahead of it. The use is migraine prevention — a daily capsule taken for months in the hope of having fewer attacks. The reputation comes from a wave of British self-medication in the 1970s and 1980s, a handful of small positive trials, and a great deal of repetition since.

The honest position is narrower than the reputation. Six double-blind randomised trials in 561 patients have tested feverfew against placebo for migraine prevention. They could not be pooled, because they used different preparations, different outcome measures and different populations. The three that were positive were the three smallest — 17, 57 and 60 participants. The two most rigorous older trials, with 50 and 147 participants, found no significant difference from placebo. The single largest and best-conducted trial found a real but small benefit: 0.6 fewer migraine attacks per month than placebo. That is the whole clinical case, and the current Cochrane review grades it as low-quality evidence.

There is a plausible reason the trials disagree, and it is the most practical thing on this page: feverfew products are not comparable to one another. When pharmacy researchers bought commercial feverfew off the shelf and measured its supposed active compound, parthenolide, the amount delivered per recommended daily dose varied 160-fold between products. In an older analysis, some products labelled “feverfew” contained no detectable parthenolide at all. A trial of a weak product and a trial of a strong one are not testing the same thing.

These four articles take that apart: what the trials actually found, what parthenolide does and the awkward bioavailability problem underneath it, how to read a feverfew label so you are not buying leaf powder at random, and the real safety picture — including the withdrawal reaction that catches long-term users who stop abruptly.

Table of Contents

  1. Deep-Dive Articles
  2. What Feverfew Is and Is Not Good For
  3. The Product-Variability Problem
  4. A Preventive, Not a Rescue Remedy
  5. Safety in Brief
  6. Key Research Papers
  7. External Resources
  8. Connections

Deep-Dive Articles

Start with migraine prevention — it is the only indication with a real trial literature. Everything else on this page is either mechanism, product quality, or safety, and all three exist mainly to explain why the migraine evidence looks the way it does.

Migraine Prevention

Every trial, one at a time, with its own sample size, preparation and result — the positive small ones, the two rigorous negatives, and the 218-patient MIG-99 study that moved the Cochrane conclusion from “inconclusive” to “low-quality positive.”

How Parthenolide Works

Serotonin release, platelet secretion, NF-κB blockade and the TRPA1 channel on trigeminal nerves — genuine pharmacology, plus the phase I trial in which 4 mg of oral parthenolide produced no detectable blood level at all.

Choosing a Product and Dosing

The 160-fold variation between commercial products, what a usable label actually states, why CO2 extract is not interchangeable with dried leaf on a milligram basis, and how long to give it before deciding.

Side Effects and Post-Feverfew Syndrome

Mouth ulcers from chewing the leaf, ragweed and chrysanthemum cross-reactivity, antiplatelet effects around surgery, why pregnancy is a hard no — and how to taper off rather than trigger rebound headache.

What Feverfew Is and Is Not Good For

A blunt map before the detail. Every row below is judged on human evidence, not on laboratory activity or tradition.

UseBest available human evidenceHonest verdict
Migraine prevention — stable CO2 extract (MIG-99)One 218-patient randomised trial (170 analysed), 16 weeks, 6.25 mg three times daily; net benefit 0.6 attacks/month over placeboThe strongest evidence feverfew has. Real, statistically significant, and small. Cochrane rates the overall body of evidence low quality
Migraine prevention — dried leaf capsulesThree small positive trials (17, 57, 60 participants) and one rigorous negative crossover trial (50 participants, 9 months)Genuinely unresolved. The positive trials were small and enrolled people who already used feverfew and could plausibly guess their allocation
Treating an attack already underwayTwo trials of a sublingual feverfew-plus-ginger product, not feverfew aloneFeverfew on its own is not an acute treatment and was never tested as one
Rheumatoid arthritisOne double-blind placebo-controlled trial, 41 women, dried leaf added to existing NSAIDsNegative. No benefit on pain, stiffness or grip strength
Fever — the use it is named afterNoneHistorical only. There is no modern clinical evidence feverfew reduces fever
Cancer (parthenolide)One phase I trial in cancer patients, which measured drug levels rather than tumour responseNot a treatment. The trial's finding was that oral parthenolide does not reach detectable blood levels

Notice what is missing: there is no trial showing feverfew helps arthritis, fever, menstrual pain, digestion or dizziness, all of which appear in its traditional indications. Traditional use tells you what people tried. It does not tell you what worked.

The Product-Variability Problem

This is the single most useful thing to understand about feverfew, and it is unusually well documented.

In 2002, pharmacy researchers at Southwestern Oklahoma State University bought commercial feverfew products and measured them by HPLC. The weight of feverfew leaf in each capsule broadly matched the label. The parthenolide content did not. Per dose form it ranged from 0.02 mg to 3.0 mg — a 150-fold spread. Following each product's own label instructions, a consumer's daily parthenolide intake would range from 0.06 mg to 9.7 mg — a 160-fold difference (Nelson 2002).

A decade earlier, an international group using three independent analytical methods plus a platelet bioassay found the same thing more starkly: purported feverfew products “varied widely in their parthenolide content and in some products parthenolide was not detected.” The same study showed parthenolide levels fell during storage of powdered leaf, and that the compound is concentrated in leaves, flowering tops and seeds but scarce in stalks and roots — so what part of the plant was harvested matters too (Heptinstall 1992).

Three consequences follow, and they run through every other page here:

  1. Trials disagree partly because they tested different drugs. The negative Dutch crossover trial used an alcoholic extract standardised to just 0.5 mg parthenolide daily. The positive MIG-99 trials used a supercritical CO2 extract reproducibly manufactured to a fixed specification. Calling both “feverfew” obscures more than it reveals.
  2. A milligram of one product is not a milligram of another. Dose numbers copied off the internet without the preparation attached are close to meaningless.
  3. Shelf life is a real variable. Parthenolide degrades. A dermatology group re-analysing a feverfew cream two years later found the parthenolide gone entirely (Paulsen 2010). An old bottle at the back of a cupboard is not the product that was tested.

A Preventive, Not a Rescue Remedy

Feverfew is studied as prophylaxis: taken every single day, whether or not you have a headache, with the aim of reducing how many attacks occur over a month. It is not something to reach for when a migraine starts. The MIG-99 trial ran 16 weeks; the Dutch crossover trial ran nine months. Benefit, where it appeared, was measured in attacks per 28 days, not in hours to relief.

Two studies did test a sublingual feverfew-and-ginger combination for treating attacks early, and the 2011 pilot reported 32 percent of patients pain-free at two hours versus 16 percent on placebo (Cady 2011). That is a different product, containing a different herb alongside feverfew, given a different way. It is not evidence that a feverfew capsule will stop a migraine, and it should not be read as such.

Practically: give a preventive a fair trial of eight to twelve weeks before judging it, keep a headache diary from before you start so you have a genuine baseline, and change one thing at a time.

Safety in Brief

Cochrane's review of the trial data concluded that only “mild and transient adverse events, most commonly gastrointestinal complaints and mouth ulcers” were reported, and that feverfew “is not associated with any major safety concerns” at studied doses. That is reassuring but not a blank cheque — trials are short, and they exclude the people most likely to run into trouble. The four situations that actually matter:

Key Research Papers

Every identifier below was checked live against NCBI E-utilities — first author, title, journal and year all had to match before a PMID was printed.

The systematic reviews

  1. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews. 2015;4(4):CD002286. Six trials, 561 patients; results could not be pooled; the one large rigorous trial adds “some positive evidence” but the body of evidence is graded low quality.
  2. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews. 2004;(1):CD002286. The previous version, whose conclusion was that the evidence did not convincingly establish an effect — the position the 2015 update revised.
  3. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia. 1998;18(10):704–708.
  4. Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. Feverfew for migraine prophylaxis: a systematic review. Journal of Dietary Supplements. 2009;6(2):91–103.
  5. Lopresti AL, Smith SJ, Drummond PD. Herbal treatments for migraine: a systematic review of randomised-controlled studies. Phytotherapy Research. 2020;34(10):2493–2517.

The individual migraine trials

  1. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention. Cephalalgia. 2005;25(11):1031–1041. The strongest trial: 170 analysed, 16 weeks, 1.9 versus 1.3 fewer attacks per month, P = 0.0456.
  2. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a dose-response study. Cephalalgia. 2002;22(7):523–532. Often described as identifying the effective dose; in fact it failed its primary endpoint overall and was positive only in a predefined 49-patient subgroup.
  3. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. The Lancet. 1988;2(8604):189–192.
  4. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal (Clinical Research Ed.). 1985;291(6495):569–573. Seventeen habitual feverfew eaters; those switched to placebo got worse. The origin of both the reputation and the withdrawal description.
  5. De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225–230. Fifty feverfew-naïve patients, nine months, 0.5 mg parthenolide daily — no effect.
  6. Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic M) in the treatment of migraine. Headache. 2011;51(7):1078–1086.

Product quality and parthenolide content

  1. Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. American Journal of Health-System Pharmacy. 2002;59(16):1527–1531. The 160-fold daily-intake finding.
  2. Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew: estimation of commercial and authenticated feverfew products. Journal of Pharmacy and Pharmacology. 1992;44(5):391–395. Some commercial products contained no detectable parthenolide.
  3. Jin P, Madieh S, Augsburger LL. Selected physical and chemical properties of feverfew (Tanacetum parthenium) extracts important for formulated product quality and performance. AAPS PharmSciTech. 2008;9(1):22–30.

Mechanism and pharmacokinetics

  1. Materazzi S, Benemei S, Fusi C, et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain. 2013;154(12):2750–2758.
  2. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. The Lancet. 1985;1(8437):1071–1074.
  3. Hehner SP, Hofmann TG, Dröge W, Schmitz ML. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. The Journal of Immunology. 1999;163(10):5617–5623.
  4. Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs. 2004;22(3):299–305. Up to 4 mg oral parthenolide daily gave no detectable plasma concentration.

Safety, allergy and other indications

  1. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Annals of the Rheumatic Diseases. 1989;48(7):547–549. Negative.
  2. Paulsen E, Christensen LP, Fretté XC, Andersen KE. Patch test reactivity to feverfew-containing creams in feverfew-allergic patients. Contact Dermatitis. 2010;63(3):146–150.
  3. Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew: is a full reproductive study warranted? Reproductive Toxicology. 2006;22(4):688–693.
  4. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78(17):1346–1353. The guideline that rated a standardised feverfew extract Level B, “probably effective.”
  5. Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacognosy Reviews. 2011;5(9):103–110.

Live PubMed Searches

  1. Tanacetum parthenium
  2. Feverfew migraine prophylaxis
  3. Parthenolide pharmacology
  4. MIG-99 feverfew extract
  5. Parthenolide content and standardisation
  6. Feverfew adverse effects
  7. Compositae sesquiterpene lactone allergy
  8. TRPA1 and trigeminal migraine pain

External Resources

Connections

Back to Table of Contents